A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 80
Inclusion Criteria
- 2nd line treatment for metastatic disease
- Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)
- Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin.
- ...
- 2nd line treatment for metastatic disease
- Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)
- Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin.
- Patients with prior adjuvant treatment are allowed.
- 1st line treatment for metastatic disease
- Patient must be able to give own signed informed consent.
- Patients were FFPE and fresh frozen tissue is available (both mandatory).
- Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
- BRAF and/or MEK inhibitors
- Adjuvant treatment
- Patients ≥ 18 years of age.
Summary
- Conditions
- Advanced Melanoma
- Metastatic Melanoma
- Type
- Observational
- Design
- Observational Model: Cohort
- Time Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- 2nd line treatment for metastatic disease
- Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)
- Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin.
- ...
- 2nd line treatment for metastatic disease
- Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)
- Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin.
- Patients with prior adjuvant treatment are allowed.
- 1st line treatment for metastatic disease
- Patient must be able to give own signed informed consent.
- Patients were FFPE and fresh frozen tissue is available (both mandatory).
- Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
- BRAF and/or MEK inhibitors
- Adjuvant treatment
- Patients ≥ 18 years of age.
Tracking Information
- NCT #
- NCT02177110
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon